A number of orally available glycosylation inhibitors are being tested in multiple clinical studies for various disorders [25], and such inhibitors, alone or in combination with other P-selectin inhibitors, may offer a novel means of inhibiting vaso-occlusive crisis in SCD. The gene discussed is SELP; the disease is Schnyder corneal dystrophy.